OTLK Earnings & Financial Statements
Outlook Therapeutics, Inc.
$0.47
-$0.09(-16.60%)
23
Overall
40
Value
10
Tech
21
Quality
Market Cap
$114.47M
Volume
9.54M
52W Range
$0.16 - $2.54
Target Price
$5.03
OTLK earnings and financial statements: Outlook Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
OTLK Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $1.41M | - | - | - | - |
| Cost of revenue | $1.36M | - | - | - | - |
| Operating income | -$67.06M | -$71.70M | -$53.13M | -$63.07M | -$51.73M |
| EBITDA | -$63.58M | -$72.09M | -$58.93M | -$64.36M | -$51.96M |
| Net income | -$62.42M | -$75.37M | -$58.98M | -$66.05M | -$53.16M |
| EPS (diluted) | $-1.79 | $-4.06 | $-4.80 | $-6.20 | $-7.00 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $18.58M | $28.82M | $32.30M | $28.53M | $22.81M |
| Total liabilities | $50.77M | $101.90M | $46.74M | $19.79M | $18.20M |
| Shareholders’ equity | -$32.19M | -$73.08M | -$14.44M | $8.74M | $4.61M |
| Cash and equivalents | $8.08M | $14.93M | $23.39M | $17.40M | $14.48M |
| Long-term debt | $188.8K | $246.9K | - | $4.3K | $10.93M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$51.83M | -$68.79M | -$42.97M | -$56.67M | -$54.25M |
| Free cash flow | -$51.83M | -$68.79M | -$42.97M | -$56.67M | -$54.25M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | OTLK | $0.47 | -16.6% | 9.54M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Outlook Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW